IAVI

Media & Resources

Fact sheets & publications

The following is a selection of recent fact sheets and policy guidance documents produced by IAVI in partnership with key stakeholders.

Download IAVI and partner publications funder acknowledgments

About IAVI

IAVI is a nonprofit organization dedicated to developing vaccines and antibodies for HIV, tuberculosis, emerging infectious diseases, and neglected diseases. Our mission is to translate scientific discoveries into affordable, globally accessible public health solutions.

The world needs an HIV vaccine

The only way to end HIV/AIDS as a public health problem of global importance is with a vaccine. IAVI remains committed to developing a safe, effective, globally useful one.

The urgent need for a TB vaccine

A vaccine is necessary to end the TB epidemic. IAVI and partners continue to make strides to reach this goal.

Emerging infectious diseases vaccines

IAVI is applying its vaccine development expertise and working with a group of expert international partners to develop vaccines to prevent emerging infectious diseases.

Antibodies for HIV prevention

IAVI and partners are applying their expertise gained from HIV vaccine research to produce what could be a breakthrough in the fight against HIV/AIDS: an injection of bnAbs to prevent HIV infection.

MTBVAC: the only live-attenuated Mtb vaccine in development

IAVI is partnering with the Spanish biopharmaceutical company Biofabri in the advanced clinical development of the MTBVAC vaccine candidate to see if it prevents TB disease in infants, adolescents, and adults. MTBVAC is the only live, attenuated vaccine candidate derived from M.tb.

IAVI Design and Development Lab

The IAVI Vaccine Design and Development Lab generates and develops innovative HIV and emerging infectious diseases vaccine candidates to address global public health needs.

ADVANCE

ADVANCE (Accelerate the Development of Vaccines and New Technologies to Combat the AIDS Epidemic) is a 5-year cooperative agreement extended through June 2026 with the U.S. Agency for International Development (USAID), through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR).

Most recent

Filter by

  • Type

  • Health area

  • Location

  • Topic

  • Year

  • Journal

  • Publication

  • Fact sheet & publication type

  • Clear all

Building and Enhancing Policy and Advocacy Skills of Civil Society Organizations, Community Based Organizations, Clinical Research Centers and Institutions in Biomedical Prevention Research — Training Manual

Developed in partnership with key stakeholders, this policy and advocacy training manual is designed to ensure that essential skills are shared and transferred among diverse audiences. Our goal is to build a critical mass of advocates who can influence policies and best practices in HIV prevention research and beyond.

Read more

Access to monoclonal antibodies in Africa: A call to action

A report from IAVI and Impact Global Health evaluating the current state of research and development and access for monoclonal antibodies (mAbs) and related products. The report, funded by Wellcome, is a four-year retrospective on the availability of mAbs and biosimilars globally — with new insights into the African region that could serve as a bellwether for progress globally.

Read more

Broadly neutralizing antibodies and their use in HIV research

Antibodies are natural proteins that the body makes that fight disease. Broadly neutralizing antibodies (bnAbs) are a special kind of antibody that is now being researched to see how they can play a role in HIV prevention.

Read more

IAVI and Partner Publications Funder Acknowledgments

A how-to guide for acknowledging funders in publications produced by IAVI and our partners.

Read more

Potential Future Options for HIV Prevention in Babies

Medical researchers are working on new options to prevent HIV in babies that offer more choices for pregnant and breastfeeding individuals to protect their babies. One of these new options is broadly neutralizing antibodies.

Read more

Antibodies for HIV prevention

IAVI and partners are applying their expertise gained from HIV vaccine research to produce what could be a breakthrough in the fight against HIV/AIDS: an injection of bnAbs to prevent HIV infection.

Read more

MTBVAC: the only live-attenuated Mtb vaccine in development

IAVI is partnering with the Spanish biopharmaceutical company Biofabri in the advanced clinical development of the MTBVAC vaccine candidate to see if it prevents TB disease in infants, adolescents, and adults. MTBVAC is the only live, attenuated vaccine candidate derived from M.tb.

Read more

IAVI 2023 Annual Report

An overview of the progress IAVI and partners made in 2023 toward our pursuit to translate scientific discoveries into affordable, globally accessible public health solutions.

Read more